ZTS 📈 Zoetis - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98978V1035
ZTS: Vaccines, Medicines, Diagnostic Products, Parasiticides, Feed Additives
Zoetis Inc. is a leading player in the animal health industry, with a diverse portfolio of medicines, vaccines, and diagnostic products and services that cater to the needs of livestock and companion animals. The company's product range spans across various species, including cattle, swine, poultry, fish, and sheep, as well as dogs, cats, and horses. Its offerings include parasiticides, vaccines, dermatology products, anti-infectives, and medicated feed additives, all of which are designed to prevent, diagnose, and treat a range of diseases and conditions that affect animals.
In addition to its pharmaceutical products, Zoetis Inc. also provides a range of diagnostic solutions, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, and reference laboratory kits and services. The company's diagnostic portfolio also includes blood glucose monitors, which are used to manage diabetes in animals. Furthermore, Zoetis Inc. offers a range of non-pharmaceutical products, such as nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. These products and services are designed to help veterinarians, livestock producers, and pet owners to better manage the health and wellbeing of their animals.
Zoetis Inc. has a strong research and development pipeline, with a focus on discovering and developing new and innovative products that address the evolving needs of the animal health industry. The company has collaborations with other organizations, such as Blacksmith Medicines, Inc., to develop novel antibiotics for animal health. With a history dating back to 1952, Zoetis Inc. has established itself as a trusted and reliable partner in the animal health industry, with a global presence and a reputation for quality and excellence. The company is headquartered in Parsippany, New Jersey, and its common stock is listed on the New York Stock Exchange under the ticker symbol ZTS.
The company's commitment to innovation and customer satisfaction has enabled it to build a strong customer base, including veterinarians, livestock producers, and pet owners. Its products and services are marketed through a range of channels, including direct sales, distributors, and online platforms. With a strong focus on research and development, Zoetis Inc. is well-positioned to continue to drive growth and innovation in the animal health industry, and to address the changing needs of its customers and the animals they care for. The company's website, https://www.zoetis.com, provides more information on its products, services, and mission.
Additional Sources for ZTS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ZTS Stock Overview
Market Cap in USD | 79,067m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2013-02-01 |
ZTS Stock Ratings
Growth 5y | 23.9% |
Fundamental | 81.7% |
Dividend | 63.1% |
Rel. Strength Industry | -813 |
Analysts | 4.28/5 |
Fair Price Momentum | 141.78 USD |
Fair Price DCF | 132.35 USD |
ZTS Dividends
Dividend Yield 12m | 1.05% |
Yield on Cost 5y | 1.36% |
Annual Growth 5y | 17.99% |
Payout Consistency | 100.0% |
ZTS Growth Ratios
Growth Correlation 3m | -80.8% |
Growth Correlation 12m | -7.1% |
Growth Correlation 5y | 47.6% |
CAGR 5y | 5.26% |
CAGR/Mean DD 5y | 0.28 |
Sharpe Ratio 12m | -0.69 |
Alpha | -39.22 |
Beta | 0.94 |
Volatility | 31.18% |
Current Volume | 6184.1k |
Average Volume 20d | 2629k |
As of December 21, 2024, the stock is trading at USD 164.84 with a total of 6,184,066 shares traded.
Over the past week, the price has changed by -8.57%, over one month by -6.86%, over three months by -15.18% and over the past year by -16.63%.
Yes, based on ValueRay Fundamental Analyses, Zoetis (NYSE:ZTS) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 81.71 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ZTS as of December 2024 is 141.78. This means that ZTS is currently overvalued and has a potential downside of -13.99%.
Zoetis has received a consensus analysts rating of 4.28. Therefor, it is recommend to buy ZTS.
- Strong Buy: 9
- Buy: 5
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ZTS Zoetis will be worth about 156.5 in December 2025. The stock is currently trading at 164.84. This means that the stock has a potential downside of -5.04%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 214.8 | 30.3% |
Analysts Target Price | 222.8 | 35.2% |
ValueRay Target Price | 156.5 | -5% |